Clinical trial · Observational
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants
Evaluating the Safety and Effectiveness of Cemiplimab in Combination With Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multi-Database Real World Evidence Study in US Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260911-000001
Summary
Brief summary (as posted)
This multi-year cohort study will assess the real-world safety and effectiveness of first Line (1L) treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC participant subgroups defined by age, sex, race, and ethnicity. Participants will be retrospectively identified from at least two US Electronic Health Record (EHR)-based databases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Platinum-doublet chemotherapy | Other | — | UNRESOLVED |
| REGN2810 | Drug | Cemiplimab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Study Participants
- description
- Participants who have received cemiplimab in combination with platinum-doublet chemotherapy for the 1L treatment of aNSCLC in the US with no documented EGFR, ALK and ROS1 variants as described in the protocol.
- interventionNames
- Drug: REGN2810
- Other: Platinum-doublet chemotherapy
Primary outcomes (5)
- measure
- Real-world Response Rate (rwRR)
- timeFrame
- Approximately 3 years
- measure
- Any treatment-emergent immune-mediated Adverse Event (imAE)
- timeFrame
- Approximately 3 years
- measure
- Any treatment-emergent imAE resulting in hospitalization
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: 1\. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol Key Exclusion Criteria: 1. Participants who have EGFR, ALK or ROS1 variants 2. Treatment with EGFR, ALK or ROS1 inhibitors at any time prior to the index date 3. Participants actively enrolled in a clinical trial in which they receive treatment with cemiplimab in combination with platinum-doublet chemotherapy Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
References
Publications (0)
Data not yet available